reports
Immuron - FY25 global sales exceed projection, up 49% on prior year
Immuron - FY25 global sales exceed projection, up 49% on prior year Sales Highlights (unaudited): Global Annual sales AUD$7.3 million up 49% on prior yearJune 2025 Quarter AUD$2.0 million up 55% on prior year Australia Annual sales AUD$5.2 million up 40% on prior yearJune 2025 Quarter AUD$1.5 million up 58% on prior year North America Annual sales AUD$2.0 million up 76% on prior yearJune 2025 Quarter AUD$0.5 million up 49% on prior year MELBOURNE, Australia, July 17, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmace...
Immuron Letter to Shareholders: Projects Update
Immuron Letter to Shareholders: Projects Update Highlights: Immuron on track to exceed A$7 million in Sales this financial yearUniformed Services University anticipates topline results of Travelan® clinical study in October 2025Immuron anticipates IMM-529 (Clostridiodes difficile infection) IND submission to the FDA in August 2025Launch plans underway for ProIBS® in AustraliaImmuron anticipates IMM-986 (Vancomycin-resistant enterococci) pre-clinical research results in August 2025 MELBOURNE, Australia, May 30, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: I...
Immuron Travelan® highest sales in history
Immuron Travelan® highest sales in history Sales Highlights (unaudited): Global Immuron exceeds AUD$5 million in sales in a fiscal year - highest sales in historyMarch 2025 Quarter AUD$1.3 million up 2% on prior yearMarch 2025 Year to Date AUD$5.3 million up 46% on prior year Australia March 2025 Quarter AUD$0.8 million down 8% on prior yearMarch 2025 Year to Date AUD$3.7 million up 34% on prior year North America March 2025 Quarter AUD$0.5 million up 28% on prior yearMarch 2025 Year to Date AUD$1.6 million up 86% on prior year MELBOURNE, Australia, April 10, 2025 (GLOBE NEWSWIRE...
Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS)
Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS) MELBOURNE, Australia, March 05, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce it has entered into an exclusive distribution agreement for the territories of Australia and New Zealand. Immuron will launch ProIBS® for the treatment of symptoms related to IBS in the retail pharmacy sales channel. Immuron has been a leader in digestive health in Australia for many years. ProIBS® will join Immuron’s product portfol...
Immuron Travelan® continued strong sales growth
Immuron Travelan® continued strong sales growth Sales Highlights: Global December 2024 Quarter AUD$2.5 million up 70% on prior quarter, up 249% on pcpDecember 2024 Half Year AUD$4.0 million up 70% on pcp Australia December 2024 Quarter AUD$1.9 million up 83% on prior quarter, up 314% on pcpDecember 2024 Half Year AUD$2.9 million up 54% on pcp North America December 2024 Quarter AUD$0.7 million up 43% on prior quarter, up 141% on pcpDecember 2024 Half Year AUD$1.1 million up 130% on pcp MELBOURNE, Australia, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Au...
Immuron Announces New Research Collaboration targeting Antimicrobial R...
Immuron Announces New Research Collaboration targeting Antimicrobial Resistance Highlights: New Research Collaboration with Monash University One proposal will target Antimicrobial Resistant Pathways to develop broad spectrum therapeutic drug productsSecond project proposal will focus on the Develop of new therapeutic drug candidates against Vancomycin-resistant enterococci (VRE) MELBOURNE, Australia, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce a new rese...
Immuron Announces Travelan® Clinical Trial Update
Immuron Announces Travelan® Clinical Trial Update Highlights: Travelan® (IMM-124E) Phase 2 Clinical Study Report submitted to the FDATravelan® (IMM-124E) Phase 2 Clinical Study Statistically Significant Immunology ResultsTravelan® (IMM-124E) Phase 2 Clinical Study Statistically Significant Microbiome ResponsesTravelan® P2TD (n=866) Uniformed Services University field study randomized 776 subjects MELBOURNE, Australia, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce th...
Immuron CEO, Steven Lydeamore to Present at the Small Cap Growth Virtu...
Immuron CEO, Steven Lydeamore to Present at the Small Cap Growth Virtual Investor Conference December 5th MELBOURNE, Australia, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at the Small Cap Growth Virtual Investor Conference hosted by VirtualInvestorConferences.com on Thursday 5th December 2024 (2.30pm U.S. Eastern time). Immuron invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com DATE...
Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Su...
Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event MELBOURNE, Australia, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore presented early this morning at the 21st Virtual Investor Summit Microcap Event (November 21, US Eastern Time). A copy of the presentation is available on the Company’s website. This release has been authorised by the directors of Immuron Limited. COMPANY CONTACT: Steven Lydeamore...
Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcar...
Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference MELBOURNE, Australia, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be participating in a fireside chat at the Maxim Virtual Healthcare Conference on Wednesday, 16th October 2024 (4.30pm U.S. Eastern time). A copy of the presentation covering information being discussed is available on the Company’s website. This release has been authorised by the directors of Immuron Limited. COMPANY CONTACT: Steven...
Immuron Travelan® continued strong sales growth
Immuron Travelan® continued strong sales growth Sales Highlights: Global• September 2024 Quarter AUD$1.5 million up 13% on prior quarter Australia• September 2024 Quarter AUD$1.0 million up 3% on prior quarter NorthAmerica• September 2024 Quarter AUD$0.5 million up 48% on prior quarter MELBOURNE, Australia, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce continued strong sales growth (unaudited) of Travelan®, an over-the-counter immune supplement that targets pathogeni...
NMRC Reports Results for Campylobacter Controlled Human Infection Mode...
NMRC Reports Results for Campylobacter Controlled Human Infection Model Study MELBOURNE, Australia, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), is an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases. Following discussion with the US Naval Medical Research Command (NMRC), today the Company can announce that the NMRC has completed the interim analysis for the clinical evaluation of a new oral therapeutic targeting Campylob...
Immuron Plans Phase 2 Trial for IMM-529 following FDA review
Immuron Plans Phase 2 Trial for IMM-529 following FDA review Key Points Immuron completes pre-IND meeting with FDA on the development of IMM-529 as product to specifically prevent or treat Clostridioides difficile infection (CDI)Previous clinical trial data on IMM-529 provides support for continued development of IMM-529 Investigational new drug (IND) application for IMM-529 planned for 1H 2025 MELBOURNE, Australia, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce th...
Immuron Announces New U.S. Department of Defense Research Award for Na...
Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan® Highlights: $3.5 (USD $2.3) million funding for NMRC and WRAIR approved by the U.S. Department of Defense to advance the development of Travelan. MELBOURNE, Australia, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce the funding of a new research agreement for the Naval Medical Research Co...
Immuron CEO, Steven Lydeamore to present at the Emerging Growth Confer...
Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference MELBOURNE, Australia, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that our Chief Executive Officer, Steven Lydeamore has been invited to present at the Emerging Growth Conference on August 22nd, 2024. Immuron Limited invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. Mr. Steven...
Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Con...
Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Connect MELBOURNE, Australia, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to invite shareholders to attend an investor webinar on MarketOpen Direct Connect to be held on: Thursday 8th August 2024, 11:00am Australian Eastern Standard Time (9:00am AWST). Chief Executive Officer, Steven Lydeamore will provide an update on additional data analysis of IMM-124E (Travelan®) Phase 2 trial and next steps. Following the presentation, attendees will have the opportunity to ask questi...
Immuron announces record Travelan® sales globally, Australia and USA
Immuron announces record Travelan® sales globally, Australia and USA Sales Highlights: Global• FY 2024 AUD$4.9 million up 174% on prior comparative period (pcp) • June 2024 Quarter AUD$1.3 million up 253% on pcp and 6% on prior quarter Australia• FY 2024 AUD$3.7 million up 223% on pcp • June 2024 Quarter AUD$1.0 million up 200% on pcp and 11% on prior quarter USA• FY 2024 Record sales of AUD$1.1 million up 74% on pcp • June 2024 Quarter AUD$0.3 million up 546% on pcp; down 1% on prior quarter Canada• FY2024 AUD$0.1 million up 6637% on pcp MELBOURNE, Australia, July 15, 20...
Immuron requests pre-IND meeting for IMM-529 with FDA filing
Immuron requests pre-IND meeting for IMM-529 with FDA filing MELBOURNE, Australia, July 02, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce that it has filed a pre-IND (investigational new drug) application with the United States Food and Drug Administration (FDA) for IMM-529. CEO, Steven Lydeamore said, “We are excited for our third therapeutic to be heading towards Phase 2 clinical studies, demonstrating the utility of our technology platform.” The increased incidence of an...
Immuron CEO, Steven Lydeamore to present at the Emerging Growth Confer...
Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference MELBOURNE, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that our Chief Executive Officer, Steven Lydeamore has been invited to present at the Emerging Growth Conference on June 13th, 2024. Immuron Limited invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. Mr. Steven L...
Immuron CEO Steven Lydeamore to present at Peak Sky High
Immuron CEO Steven Lydeamore to present at Peak Sky High MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to advise our Chief Executive Officer Steven Lydeamore will be presenting at Peak Asset Management’s Peak Sky High luncheon in Melbourne on June 1, 2024. A copy of the presentation slide deck is available on the Company’s website. This release has been authorised by the directors of Immuron Limited. COMPANY CONTACT:Steve...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.